Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009
Author Information
Author(s): Uphoff Helmut, an der Heiden Matthias, Schweiger Brunhilde, Campe Hartmut, Beier Dietmar, Helmeke Carina, Littmann Martina, Haas Walter, Buda Silke, Faensen Daniel, Feig Marcel, Altmann Doris, Wichmann Ole, Eckmanns Tim, Buchholz Udo
Primary Institution: Hessisches Landes Prüfungs - und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany
Hypothesis
What is the effectiveness of the AS03-adjuvanted vaccine against the pandemic influenza virus A/(H1N1) 2009?
Conclusion
The AS03-adjuvanted vaccine showed good effectiveness against the pandemic influenza virus A/(H1N1) 2009, particularly in children.
Supporting Evidence
- The positivity rate of vaccinated persons decreased with increasing interval between vaccination date and illness date.
- The number of vaccinated cases in the database of reported cases decreased to low numbers for those vaccinated more than 10–14 days before illness onset.
- Both methods yielded similar vaccine effectiveness estimates in both age groups.
Takeaway
The vaccine helped protect people from getting sick with the flu, especially kids, showing it works well.
Methodology
The study used two methods: a test-negative case-control method and a case-series method to evaluate vaccine effectiveness.
Potential Biases
There may be biases in how cases were reported and the timing of vaccinations.
Limitations
The study had limitations including potential biases in case counts and the dynamic geographical course of the epidemic.
Participant Demographics
The median age of participants was 12 years, with a bimodal age distribution of cases.
Statistical Information
P-Value
0.007
Confidence Interval
95% CI = 35–93%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website